Cellerant Therapeutics

09/24/2018

July 23, 2018
Cellerant Therapeutics, Inc. Publishes Preclinical Data Highlighting Potential of Its CLL1-Targeting Antibody-Drug Conjugate to Treat Acute Myeloid Leukemia

https://www.cellerant.com/investor/press-releases/cellerant-therapeutics-inc-publishes-preclinical-data-highlighting-potential-of-its-cll1-targeting-antibody-drug-conjugate-to-treat-acute-myeloid-leukemia/

09/24/2018

July 2, 2018
Cellerant Therapeutics, Inc. Announces FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation for romyelocel-L to Prevent Infections During Neutropenia

https://www.cellerant.com/investor/press-releases/cellerant-therapeutics-inc-announces-fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-for-romyelocel-l-to-prevent-infections-during-neutropenia/

09/24/2018

June 4, 2018
Cellerant Therapeutics, Inc. CLT-008 Phase 2 Results Show Significant Reduction in Infections and Days in Hospital in Severely Neutropenic AML Patients

https://www.cellerant.com/investor/press-releases/cellerant-therapeutics-inc-clt-008-phase-2-results-show-significant-reduction-in-infections-and-days-in-hospital-in-severely-neutropenic-aml-patients/

09/24/2018

August 22, 2017
Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From California Institute for Regenerative Medicine to Support Development of Novel Antibody- Drug Conjugate for AML

https://www.cellerant.com/investor/press-releases/cellerant-therapeutics-inc-awarded-6-86-million-grant-from-california-institute-for-regenerative-medicine-to-support-development-of-novel-antibody-drug-conjugate-for-aml/

09/06/2018

http://www.amlglobalportal.com/medical-information/pinkal-desai-eha-2018-clt008-reduces-serious-infections-antibiotic-use-and-days-of-hospitalization-during-aml-induction

Pinkal Desai: Weill Cornell Medicine, New York, US. Interview topic: CLT008 reduces serious infections, antibiotic use and days of hospitalization during AML induction